A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
A phase 1/2 trial of VS-7375, Cetuximab, Carboplatin in pancreatic ductal adenocarcinoma and non-small-cell lung cancer, run by Verastem, Inc., now recruiting.
Overview
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors is a phase 1/2 interventional study registered as NCT07020221 by Verastem, Inc., with 295 participants planned, started 2025-06-24 and due to reach its primary completion in 2028-12. Interventions recorded: VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine, Gemcitabine + Nab-paclitaxel. Conditions listed: Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Shares VS-7375, Verastem Oncology, Cetuximab, Pancreatic ductal adenocarcinoma.
- TrialA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Shares VS-7375, Verastem Oncology, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance
Shares Cetuximab, Gemcitabine, Pembrolizumab, Small-cell lung cancer.
- TrialA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Shares VS-7375, Verastem Oncology, Cetuximab, Colorectal cancer.
- TrialA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm
Shares Pemetrexed, Gemcitabine, Carboplatin, Pembrolizumab.
- TrialStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Shares Cetuximab, Pemetrexed, Carboplatin, Pembrolizumab.
- TrialA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung
Shares Pemetrexed, Carboplatin, Pembrolizumab, Small-cell lung cancer.
- TrialA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Shares Pemetrexed, Gemcitabine, Carboplatin, Pembrolizumab.